{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 2 of 2 results
Status:
Investigational
Source:
NCT03681093: Phase 3 Interventional Completed Nasal Polyps
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.
